MD Biosciences

09/04/2025

Our first day at NeuPSIG in Berlin! We presented on neuropathic pain research and had the chance to meet with others in the field.

08/26/2025

NeuPSIG 2025 is around the corner! Let us know if you’ll be attending, we’d love to meet.

Reach out to us here: https://hubs.la/Q03Fh1qy0

07/22/2025

Pleased to share our involvement in a recently published study investigating the pharmacokinetics and safety of a liposomal synthetic cannabidiol (LPT-CBD) formulation in pigs.

🔗 https://hubs.la/Q03ygJKR0

By Eyal Kalo, Keith Nelson & 8 more. In this work, liposomal CBD and its major human metabolite. 7-COOH-CBD was compared in rabbits and minipigs to provide initial data on PK and safety profiles.

07/15/2025

Translating preclinical findings into clinical success remains a major challenge in drug development.

At MD Biosciences, we focus on enhancing clinical relevance of preclinical models to better predict therapeutic outcomes and support more informed decision-making. Continue reading about our approach to preclinical study design here: https://hubs.la/Q03xklyn0

Enhance the clinical relevance of preclinical studies by integrating comorbidities, using back-translation, and employing large animal models for more accurate therapeutic predictions.

07/10/2025

Studying stroke and cortical injury requires models that reflect the complexity of neurodegenerative conditions.

Our models incorporate relevant variables such as age, s*x, and diabetes to better reflect the diversity and complexity of clinical settings.

🧠 Learn more about our neurodegeneration models: https://hubs.la/Q03wDxj10

🔗 Download our stroke and ischemia model datasheet: https://hubs.la/Q03wDrxV0

🧬 View the cortical trauma injury (CTI) datasheet: https://hubs.la/Q03wDsHW0

📄 Read our whitepaper on diversity in preclinical research: https://hubs.la/Q03wDsGW0

Neurological and CNS research services, featuring clinically-relevant read outs and endpoints. Models in Multiple Sclerosis, Parkinson's disease and more

06/25/2025

New MDB Blog Post: Behavioral assessments paired with physiological readouts enhance understanding of neurological disorders in preclinical models.

🔗https://hubs.la/Q03tBkCN0

Explore behavioral assessments in preclinical models to understand motor and cognitive deficits for neurological diseases.

06/18/2025

Our diabetic models in pigs and rodents are powerful tools to study neuropathy and impaired wound healing. With behavioral, electrophysiological, and biomarker readouts, they offer translational insights into disease mechanisms and therapeutic response. Learn more about the models here: https://hubs.la/Q03sxF8S0

07/31/2024

We are excited to attend the IASP 2024 World Congress on Pain from August 5-9 this year! If you are attending and would like to schedule a meeting with us, please reach out via email at neuro@mdbiosciences.com. We look forward to connecting!

07/23/2024

We are excited to invite you to an upcoming webinar focused on the post-operative translational model. In this webinar, we will explore the challenges in developing new post-surgical pain agents, the use of preclinical animal models for surgical pain, and a success story of translating the pig post-operative pain model to the clinic.

Register here today: https://hubs.ly/Q02HGhq90

06/26/2024

Exciting update from the Swine in Biomedical Research Conference 2024! 🌟 We presented our newest model for evaluating nerve repair technologies in large animals with our poster, "Post Surgical Pain Model in Swine: New Findings". Our study explores behavioral assessments, immunohistochemistry, and s*x differences to enhance pain management strategies in large animal models. We are looking forward to advancing these strategies further!

View the poster here to explore our latest advancements in translational research: https://hubs.la/Q02DplC80

06/13/2024

Explore our diverse array of Parkinson's Disease models, including 6OHDA and MPTP rodent models, as well as neurodegeneration screening assays. We continue to further our understanding of the pathological processes underlying PD and provide effective systems for assessing therapeutic interventions. Download our datasheet to learn more! https://hubs.la/Q02BJHyZ0

05/22/2024

Learn more about our preclinical efficacy models of chemotherapy-induced peripheral neuropathy and the importance of diversity in preclinical studies. https://hubs.la/Q02y0sZ-0

Learn about preclinical efficacy models for Chemotherapy-Induced Peripheral Neuropathy (CIPN) using in vitro and in vivo methods. Understand how these models are crucial for advancing cancer treatment outcomes and alleviating patient suffering.